2009
DOI: 10.1136/bmj.b4677
|View full text |Cite
|
Sign up to set email alerts
|

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

Abstract: Objective To generate evidence on the longer term cost effectiveness of disease modifying treatments in patients with relapsing-remitting multiple sclerosis.Design Prospective cohort study with historical comparator.Setting Specialist multiple sclerosis clinics in 70 centres in the United Kingdom.Participants Patients with relapsing-remitting multiple sclerosis who started treatment from May 2002 to April 2005 under the UK risk sharing scheme.Interventions Treatment with interferon beta or glatiramer acetate i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
79
0
1

Year Published

2010
2010
2016
2016

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 87 publications
(81 citation statements)
references
References 16 publications
1
79
0
1
Order By: Relevance
“…21 However, UK authorities have yet to reduce the drugs' prices because of various controversies surrounding the analysis. Measuring the drugs' effects has proved difficult because of the varying course of the disease and because the measurement is subject to interrater variability.…”
Section: -12mentioning
confidence: 99%
“…21 However, UK authorities have yet to reduce the drugs' prices because of various controversies surrounding the analysis. Measuring the drugs' effects has proved difficult because of the varying course of the disease and because the measurement is subject to interrater variability.…”
Section: -12mentioning
confidence: 99%
“…They reduce relapses by approximately 30%, though evidence they truly affect the long-term outcome of MS is sparse. 4,5 These drugs have also been trialled in patients who have experienced a single attack or 'clinically isolated syndrome' (CIS) (ie before MS has been confirmed), in the hope treatment would delay or even prevent the development of MS. All these studies showed similar results: a statistically significant delay in the time to development of MS. Sounds impressive?…”
Section: Modern Approaches To Multiple Sclerosis Martin Wilsonmentioning
confidence: 99%
“…Prices could be set at launch based on this standard and the projected incremental QALYs per treated patient, and then be revised over time as better data became available on the actual QALYs delivered. Indeed, the current NHS "risk-sharing" scheme for several multiple sclerosis drugs is an ongoing test of the ability to adjust rewards ex post after setting a provisional ex ante price [16].…”
Section: Value-based Pricing and Reimbursement To Promote Global Innomentioning
confidence: 99%